Circulating tumor cells before and during follow-up after breast cancer surgery

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 407-413

  Van Dalum, Guus ^a   Van Der Stam, Gert Jan ^a   Tibbe, Arjan G J ^a   Franken, Bas ^b   Mastboom, Walter J B ^b   Vermes, Ivan ^b   De Groot, Marco R ^b   Terstappen, Leon W M M ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Breast cancer; Breast cancer related death; Circulating tumor cells; Progression free survival

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BLOOD; BREAST NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; MASTECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; SURVIVAL; TREATMENT OUTCOME; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84917709016     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2694     Document Type: Article

References (49)

1. P arkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Boyages J, Chua B, Taylor R, Bilous M, Salisbury E, Wilcken N and Ung O: Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg 89: 789-796, 2002.
3. Colomer R, Viñas G, Beltran M, et al: Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM). J Clin Oncol 22: 961-962, 2004.
4. Lundin J, Lehtimäki T, Lundin M, et al: Generalisability of survival estimates for patients with breast cancer - A comparison across two population-based series. Eur J Cancer 42: 3228-3235, 2006.
5. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23: 2716-2725, 2005.
6. Cronin M, Pho M, Dutta D, et al: Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164: 35-42, 2004.
7. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
8. P erou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
9. Wang Y, Klijn JGM, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679, 2005.
10. West M, Blanchette C, Dressman H, et al: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98: 11462-11467, 2001.
11. V an 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
12. Meng S, Tripathy D, Frenkel EP, et al: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10: 8152-8162, 2004.
13. V essella RL, Pantel K and Mohla S: Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther 6: 1496-1504, 2007.
14. Fehm T, Braun S, Muller V, et al: A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107: 885-892, 2006.
15. Braun S and Marth C: Circulating tumor cells in metastatic breast cancer - toward individualized treatment? N Engl J Med 351: 824-826, 2004.
16. Braun S, Vogl F and Naume B: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793-802 2005.
17. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904, 2004.
18. Cristofanilli M and Budd G: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Engl J Med 351: 781-791, 2004.
19. Liu MC, Shields PG, Warren RD, et al: Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27: 5153-5159, 2009.
20. P ierga JY, Hajage D, Bachelot T, et al: High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 23: 618-624, 2012.
21. Bidard F, Peeters D and Fehm T: Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15: 406-414 2014.
22. Franken B, de Groot MR, Mastboom WJB, Vermes I, van der Palen J, Tibbe AGJ and Terstappen LWMM: Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res 14: R133, 2012.
23. Mathiot C, Brain E, Delaloge S, Pierga J, Marty M, Giachetti S and de Cremoux P: Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14: 7004-7010, 2008.
24. Jueckstock JK, Rack BK, Zwingers T, Hepp PGM, Schneeweiss A Beckmann MW, Lichtenegger W, Sommer HL, Pantel K, Tesch H, Forstbauer H, Lorenz R, Rezai M, Neugebauer JK, Andergassen U, Friese K, et al: Prognostic relevance of circulating tumor cells (CTC) before adjuvant chemotherapy in patients with breast cancer: results of the German SUCCESS trial. J Clin Oncol 29 (Suppl): 1033, 2011.
25. Lucci A, Hall CS, Lodhi AK, et al: Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13: 688-695, 2012.
26. Janni WJ, Rack BK, Terstappen LWmm, et al: A pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer. Cancer Res 73 (Suppl 24): PD6-6, 2013.
27. Bidard FC, Mathiot C, Delaloge S, et al: Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 21: 729-733, 2010.
28. National guidelines breast cancer (richlijn mamacarcinoom 2008). [http://www.cbo.nl].
29. R Core Team: R: A Language and Environment for Statistical Computing. Version 3.0.1 (2013-05-16).
30. Coumans FAw, Ligthart ST, Uhr JW and Terstappen LWMM: Challenges in the enumeration and phenotyping of CTC. Clin cancer Res 18: 5711-5718, 2012.
31. Coumans FAW, Ligthart ST and Terstappen LWmm: Interpretation of changes in circulating tumor cell counts. Transl Oncol 5: 486-491, 2012.
32. Barradas AM and Terstappen LWMM: Towards the biological understanding of CTC: capture technologies, definitions and potential to create metastasis. Cancers (Basel) 5: 1619-1642, 2013.
33. Fischer JC, Niederacher D, Topp SA, et al: Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci USA 110: 16580-16585, 2013.
34. Coumans FAW, Siesling S and Terstappen LWMM: Detection of cancer before distant metastasis. BMC Cancer 13: 283, 2013.
35. P ierga JY, Bidard FC, Mathiot C, et al: Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14: 7004, 2008.
36. V an Dalum G, de Groot M, Stam GJ, et al: Importance of circulating tumor cells in newly diagnosed colorectal cancer. In: Proc 105th Annual Meeting Amer Assoc for Cancer Res, San Diego, CA, abst 3064, 2014.
37. Ligthart ST, Coumans FAW, Attard G, Cassidy AM, de Bono JS and Terstappen LWMM: Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One 6: e27419, 2011.
38. Swennenhuis JF, Tibbe AGJ, Levink R, Sipkema RCJ and Terstappen LWMM: Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A 75: 520-527, 2009.
39. Swennenhuis JF, Reumers J, Thys K, Aerssens J and Terstappen LWMM: Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. Genome Med 5: 106, 2013.
40. K lein CA, Blankenstein TJF, Schmidt-Kittler O, Petronio M, Polzer B and Stoecklein NH: Mechanisms of disease Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360: 683-689, 2002.
41. Meng S, Tripathy D, Shete S, et al: uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103: 17361-17365, 2006.
42. Fehm T, Sagalowsky A, Clifford E, et al: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8: 2073-2084, 2002.
43. Meng S, Tripathy D, Shete S, et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101: 9393-9398, 2004.
44. Uhr JW and Pantel K: Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA 108: 12396-12400, 2011.
45. Sieuwerts AM, Kraan J, Bolt J, et al: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101: 61-66, 2009.
46. Mostert B, Kraan J, Sieuwerts AM, et al: CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett 319: 49-55, 2012.
47. Coumans FAW, van Dalum G, Beck M and Terstappen LWMM: Filter characteristics influencing circulating tumor cell enrichment from whole blood. PLoS One 8: e61770, 2013.
48. Hou HW, Warkiani ME, Khoo BL, et al: Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep 3: 1259, 2013.
49. V ona G, Sabile A, Louha M, et al: Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 156: 57-63, 2000.